Drugs M&A Wednesday, October 21, 2026 -0.60 Negative

Merger Deal to Consider Rankin-Based Valuation

Drugs Made In America Acquisition Corp. amended a merger agreement with Power Analytics Global Corp. to allow for a standalone business combination closing at a lower valuation if the target company fails to acquire APQC Inc. by Nov. 1. The amendment addresses the withdrawal of a previous financial opinion and establishes a new valuation standard for the transaction.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed